Overview

A 680-gene next-generation sequencing panel focused on lung solid tumors bundles broad genomic coverage with the validation discipline that clinical use requires. For laboratories and distributors, the gene content is only half the story; the analytical and clinical evidence behind the assay, and the certifications that let it be offered, decide whether it can actually enter routine care and withstand regulatory scrutiny.

Analytical and Clinical Validation

A panel intended for clinical reporting must demonstrate sensitivity, specificity, and a defined limit of detection across its targets, validated on the sample types it accepts, typically formalin-fixed paraffin-embedded tissue and plasma. Validation should show how the assay behaves on low tumor-burden or low-input samples and how confidently it calls single nucleotide variants, small insertions and deletions, and copy-number or fusion events. Without this evidence, a long gene list is a research tool, not a clinical one, and should not be used to guide therapy.

Companion Diagnostic and Laboratory Certification

Where the panel reports genes tied to approved therapies, the relevant claims may carry companion diagnostic status that constrains how results are used. The performing laboratory should hold the appropriate certification for clinical testing, such as CLIA in the United States or an equivalent accredited status elsewhere, and should document its validation for each lung-relevant target. Buyers should confirm which results are reportable for treatment decisions versus informational only, since mixing the two creates clinical risk.

Bioinformatics and Report Governance

Sequence data is only as trustworthy as the pipeline that calls variants. The panel should run on a version-controlled bioinformatics workflow with a defined reference, curated variant databases, and an audit trail linking every reported call back to the raw read. A governance process for updating knowledge bases, handling incidental findings, and correcting calls keeps the report defensible over time and supports the downstream tumor board that acts on it.

Documentation and Chain of Custody

Reliable clinical genomics depends on unbroken sample tracking from collection to report. A defensible workflow records accessioning, extraction, sequencing, bioinformatics version, and variant review, with audit trails for every step. For the purchasing team, asking for the standard operating procedures and the quality dashboard a vendor maintains is the practical way to confirm that the 680-gene content is backed by process control rather than promised alone.

FAQ

Q: What validation should a 680-gene lung panel demonstrate? A: Analytical and clinical validation covering sensitivity, specificity, limit of detection, and performance on accepted sample types such as FFPE tissue and plasma.

Q: Does the panel function as a companion diagnostic? A: It may report genes with companion diagnostic status; the exact reportable claims depend on the laboratory's validation and local regulatory approvals.

Q: Which sample types are supported by the assay? A: The panel is validated on common formats including formalin-fixed paraffin-embedded tissue and plasma circulating tumor DNA, each with defined pre-analytical requirements.